Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sipuleucel-T

- PMLiVE

Sanofi’s Aubagio backed by NICE

Oral MS drug recommended for NHS use in England and Wales

Pfizer’s Jonathan Emms to be ABPI president

Will take over from MSD's Deepak Khanna in April

- PMLiVE

Pfizer ups the ante on clinical transparency

Revamps access to data portal

National Institute for Health and Care Excellence NICE logo

NICE wants more info on Genzyme’s MS drug

UK health guidance body turns down Lemtrada in draft guidance

National Institute for Health and Care Excellence NICE logo

NICE backs two eye treatments

Novartis’ Lucentis and Alimera’s Iluvien received green light for NHS use

- PMLiVE

ViiV’s Tivicay for HIV on course for EU approval

More positive news for GSK, Pfizer and Shionogi joint venture

- PMLiVE

GSK and Pfizer combine melanoma drugs in new trial

Will investigate effects of adding palbociclib to Mekinist

- PMLiVE

Pfizer extends optimisation campaign

Pharma company supports efforts to ensure public get best out of medicines

- PMLiVE

How Pfizer reclaimed its Twitter brand

Company explains how it took back its name on the social network

Pfizer finally acquires the @pfizer name on Twitter

Will streamline its existing @pfizer_news account

- PMLiVE

Scotland first in UK to back Pfizer’s Inlyta

SMC also recommends Astellas' Xtandi but not Pfizer's Bosulif

National Institute for Health and Care Excellence NICE logo

NICE denies early use of Janssen’s Velcade

Draft guidance doesn't recommend expanded bone marrow cancer indication

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links